Is avatrombopag/Sucoxin already covered by medical insurance?

Avatrombopag is a drug used to treat thrombocytopenia associated with chronic liver disease and immune thrombocytopenia (ITP), especially in adult patients who require an increase in platelet counts during diagnostic procedures or surgery. The drug promotes the production of platelets in the bone marrow by activating platelets to produce necrosis factor, thereby effectively improving the patient's platelet levels.

At present, avatrombopag is already on the market in China and has been included in Class B medical insurance. This means that eligible patients can enjoy certain Medicare reimbursements when using the drug, but only in specific patient groups. These patients are mainly patients with thrombocytopenia caused by chronic liver disease and can apply for medical insurance reimbursement when undergoing elective diagnostic procedures or surgeries. This policy greatly reduces the financial burden on patients and makes it more convenient for them to receive the treatment they need.

In terms of price, the common specifications of avatrombopag are20mg*15 tablets and 20mg*10 tablets. The price of each box is about 7,000 yuan. This price is at a moderate level compared to other similar drugs. When considering cost-effectiveness, patients need to evaluate the efficacy of the drug, the necessity of its use, and its impact on quality of life.

From a clinical application perspective, avatrombopag can effectively increase platelet counts in patients with chronic liver disease and reduce their risk of bleeding during surgery, which is particularly important for patients in need of surgery. Compared with traditional platelet transfusion, avatrombopag can provide a more stable and lasting platelet-increasing effect with relatively few side effects and is easy to use.

However, due to limitations in medical insurance reimbursement, only eligible patients can enjoy this policy, which may put some patients under greater financial pressure, especially when drug prices are high. Therefore, when patients seek medical treatment, it is recommended to communicate with the doctor to understand whether their indications meet the conditions for medical insurance reimbursement, and actively seek fee reductions or related channels from the hospital.

Reference materials:https://go.drugbank.com/drugs/DB11995